nature at BIO International Convention 2007 homepage

Licensing Executive Profiles

With activities officially beginning May 6 and lasting until the closing reception in the evening of May 9, the Biotechnology Industry Organization�s (BIO) International Convention 2007 takes place in Boston. More than 19,000 attendees are expected from all over the world (exhibitors include everyone from Maine Biotech to Malaysian Biotechnology Corp.) to network, mingle and consider biotech�s finer aspects. If you are able to make it, stop by Nature's booth Number 2522 and pick up a sample copy of Nature Biotechnology, Nature Reviews Drug Discovery, Nature Methods or one of Nature's other popular titles.

We will be providing coverage via podcasts, as well as blogs on site at BIO International Convention. If you can't attend, our reports will let you know what it's like inside the convention, at the receptions and in the audience for keynote presentations. If you are attending, check here for additional insight or for things you might have missed.

BIO International Convention Podcast

Allan Coukell, of Boston's National Public Radio station WBUR, Nature Biotechnology's John Hodgson and BioCentury's Mike Ward host a series of four podcasts from the BIO International Convention. Each show will include interviews with key figures as well as incisive comment, analysis and gossip from the day's events.

You can sign up and have each show delivered straight to your desktop as we publish them. To do this, paste the URLs below into the "Advanced" menu in iTunes, or your podcasting software.

http://www.nature.com/conferences/bio2007/rss/index.xml

Alternatively, you can listen to each show at your computer by clicking on the link below:

BIO International Convention Podcast - Wednesday

BIO International Convention Podcast - Tuesday

BIO International Convention Podcast - Monday

BIO International Convention Podcast - Teaser

For more information, go to www.nature.com/nature/podcast/help.html

BIO International Convention

Blog@BIO International Convention hosts content by the editors of Nature Biotechnology as well as bloggers prominent in the industry - a forum for our readers, authors and the entire biotech community. Our editors, news writers and contributors will be on site in Boston, commenting on the meeting, the science, the gossip — Keep checking Blog@BIO International Convention for updates on what promises to be an exciting meeting.

Nature Network Boston

Talk about the day's events with other BIO International Convention attendees on Nature Network Boston, the online meeting place for scientists and entrepreneurs.�Join the “BIO International Convention” group and start posting comments in the group's forum. Discuss your reactions to the sessions, point others to good booths to visit or even give restaurant recommendations. If you sign up and join this forum before the meeting ends, you'll be entered into a draw for a $200 American Express gift card.

Bioentrepreneur Gateway

Bioentrepreneur is Nature Publishing Group's one stop resource for researchers hoping to commercialize their research, and for those working for and with young life science companies. Content is authoritative, independent advice provided by experts and industry insiders.

Special Content from NPG
Special Content from NPG

A collection of free content from Nature Biotechnology, Nature Reviews Drug Discovery and other NPG titles related to this meeting.

NEWS FEATURES

Finding the moral high ground
Ken Howard Wilan &�Laura DeFrancesco

Where the money is
Michael Fitzgerald

Price controls seen as key to Europe's drug innovation lag
Peter Mitchell

Big pharma slims down to bolster productivity
Joanna Owens

Cancer nanotechnology: small, but heading for the big time
Dan Jones

2006 drug approvals: finding the niche
Joanna Owens

Pharma faces major challenges after a year of failures and heated battles
Simon Frantz

COMMENTARY

Navigating the future(s) of biotech intellectual property
Kenneth Neil Cukier

Fates intertwined
Garth J S Cooper

Who took the tech out of biotech?
Elizabeth Silverman

Price controls: preparing for the unthinkable
Stephan Herrera

Crystal gazing: biotech's financial outlook
Eric Schmidt & David J Strupp

From oligos to Oprah – the consumer and biotech
Paul Oestreicher, Tim Warner & John Mack

Biogenerics at the crossroads
Carole S Ben-Maimon & Rob Garnick

Ten years of biotech gaffes
John Hodgson

Whither agbiotechnology?
L Val Giddings

Convergence in biomedical technology
Ascher Shmulewitz, Robert Langer & John Patton

Welcome to the body-wide web
David Shenk

Building biomanufacturing capacity – the chapter and verse
Michael E Kamarck

FEATURES

Ethical decision-making in bioscience firms
David Finegold & Allison Moser

Who's who in biotech
K S Jayaraman, Sabine Louët, Kendall Powell, John Ransom, Cormac Sheridan, Brian Vastag & Emily Waltz

Ten years of Nature Biotechnology research
Monya Baker

Off the beaten path
Jonathan Buckley, Jorge Gatica, Mark Tang, Halla Thorsteinsdóttir, Alok Gupta, Sabine Louët, Min-Chol Shin & Mark Wilson

Gold in the ivory tower: equity rewards of outlicensing
Mark Edwards, Fiona Murray & Robert Yu

Public biotechnology 2005 – the numbers
Riku Lähteenmäki & Stacy Lawrence

Private biotech 2004 – the numbers
John Hodgson

Biopharmaceutical benchmarks 2006
Gary Walsh

Can biofuels finally take center stage?
Charlotte Schubert

New-wave diagnostics
Monya Baker

The business of developing antibacterials
Jeffrey L Fox

Dolly for dinner? Assessing commercial and regulatory trends in cloned livestock
J Suk, A Bruce, R Gertz, C Warkup, C B A Whitelaw, A Braun, C Oram, E Rodr�guez-Cerezo & I Papatryfon

Turning biodefense dollars into products
Melanie C Trull, Tracey V du Laney & Mark D Dibner

PERSPECTIVES

Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers
Mark R. Trusheim, Ernst R. Berndt & Frank L. Douglas

How many drug targets are there?
John P. Overington, Bissan Al-Lazikani & Andrew L. Hopkins

Drugs, their targets and the nature and number of drug targets
Peter Imming, Christian Sinning & Achim Meyer

Can open-source R&D reinvigorate drug research?
Bernard Munos

Diagnostics and biomarker development: priming the pipeline
Kathryn A. Phillips, Stephanie Van Bebber & Amalia M. Issa

CAREERS

Building bioclusters

Creating a company

Making the right move

Nature Biotechnology is the source for today�s most up-to-date information on the science and business of biotechnology. Subscribe and receive your 20% discount to Nature Biotechnology, or visit Nature Publishing Group at BIO International Convention in Boston, MA, May 7-9, booth number 2522. This offer expires May 31st, so hurry!